This notice does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure "open procedure" (section IV.1.1) used in this notice is due to the requirements of the Notice Form. Hereby, as well as with the use of the medium "TED", no submission is subject to procurement regulations whose validity is not prescribed by law or public procurement regulations. It is a framework contract with accession option, which refers to various active ingredients.
The subject-matter of the present invention is medicaments containing the active substance bortezomib in an individually prepared parenteral preparation of finished medicinal products or in a dispensed finished medicinal product.
Subject of the agreement are medicines containing the active substance follitropin beta.
The subject of the agreement are medicinal products containing the active ingredient combination formoterol and beclomethasone.
The subject of the agreement is medicinal products containing the active ingredient fulvestrant in standard size N3.
The subject of the agreement is medicinal products containing the active substance goserelin.
The subject of the agreement is medicinal products containing the active substance interferon beta-1a (Avonex®).
The subject matter of the present invention is medicaments containing the active substance octreotide in a parenteral depot dosage form.
Subject of the invention are medicines containing the active substance paliperidone palmitate in a parenteral depot dosage form.
The subject of the agreement is medicinal products containing the active substance piribedil.
The subject of the agreement is medicinal products containing Reviparin.
Subject of the invention are medicines containing the active substance risperidone in a parenteral depot dosage form.
The subject-matter of the present invention are medicaments containing the active ingredient ciclosporin in an ophthalmological dosage form in single-dose pipettes.
The subject-matter of the present invention is medicaments containing the active ingredient rituximab in an individually prepared parenteral preparation of finished medicinal products or in a dispensed finished medicinal product.
The subject of the agreement are medicinal products containing the active substance tinzaparin.
The subject matter of the present invention is medicaments containing the active substance tobramycin in the form of a hard capsule with powder for inhalation.
The subject of the agreement is medicaments containing the active substance trastuzumab in potency 420 mg per unit pack in an individually prepared parenteral preparation of finished medicinal products or in a dispensed finished medicinal product.
The subject of the agreement is medicinal products containing the active substance dalteparin sodium.
The subject of the agreement is medicinal products containing the active substance darbepoetin.
The subject of the agreement is medicinal products containing the active substance epoetin beta.
The subject of the agreement is medicinal products containing the active substance epoetin zeta.
The subject of the agreement is medicinal products containing the active substance erlotinib.
The subject of the agreement are medicines containing the active substance combination estradiol and cyproterone.
The subject of the agreement is medicinal products containing the active substance fentanyl (patch).